深化ESG与经营战略融合 兴齐眼药锚定可持续发展目标

Core Viewpoint - The company, Xingqi Eye Medicine, aims for high-quality sustainable development during the "14th Five-Year Plan" period, integrating Environmental, Social, and Governance (ESG) principles into its operations to enhance both business performance and social responsibility [2][3]. Group 1: Financial Performance - From 2021 to 2024, the company's revenue is projected to increase from 1.028 billion yuan to 1.943 billion yuan, while net profit attributable to shareholders is expected to rise from 195 million yuan to 338 million yuan, significantly outpacing industry averages [2]. - The company has distributed a total of 1.166 billion yuan in cash dividends over nine years, reflecting its commitment to returning value to investors [3]. Group 2: ESG Integration - Xingqi Eye Medicine has established an ESG committee within its board to deeply integrate ESG into its strategy and operations, creating a "BRIGHT" ESG management system [2]. - The company emphasizes transparency by disclosing ESG results to stakeholders, aiming to gain recognition through standardized governance frameworks and clear accountability [2]. Group 3: Environmental Responsibility - The company incorporates green and low-carbon principles throughout its processes, optimizing production techniques and reducing energy consumption and carbon emission intensity [2]. - Xingqi Eye Medicine has been recognized as a "waste-free factory" and a "national-level green factory," with its practices selected as potential case studies for the Ministry of Ecology and Environment's 2025 ESG initiative [2]. Group 4: Product Development - The company has maintained a research and development investment ratio exceeding 10% for five consecutive years, focusing on ophthalmic health [3]. - In March 2024, the company received approval for a myopia delay drug, the first of its kind in China, filling a significant gap in the domestic market [3]. - The approval of different concentrations of atropine eye drops in January 2026 will create a tiered product matrix alongside existing offerings [3]. Group 5: Future Vision - Looking ahead to the "15th Five-Year Plan," the company aims to become a globally competitive ophthalmic pharmaceutical enterprise, further integrating ESG with its business strategy to create long-term value for shareholders and society [3].